linjc16/ctgov huggingface dataset:
Chairside Mouthrinse Test and Cost Effectiveness

Study Overview
=================
Brief Summary
-----------------
The aim is to study whether participants at risk could be identified using an aMMP-8 chairside mouth rinse test and to study if oral health and health behaviour is linked to the test result in Finnish adolescents.

Detailed Description
-----------------
Adolescents (14-15-year-olds) are randomly divided to control group and test group. Chairside mouth rinse test for aMMP-8 is performed for the test group. Two groups are compared with each other. Participants are asked to fill a questionnaire which consists of questions concerning oral hygiene habits, tobacco products, alcohol, drug and snuff use.

Official Title
-----------------
Pilot Study on Oral Health Status Chairside Mouthrinse Test in Finnish Adolescents and Cost Effectiveness of the Test

Conditions
-----------------
Periodontitis, Juvenile

Intervention / Treatment
-----------------
* Diagnostic Test: aMMP-8 chairside test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All 8 class (aged 14-15 years) pupils in Jukola, Hämeenlinna, Finland Written informed consent from the participants and their parents (one of them) Exclusion Criteria: No written consent to the study

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: aMMP-8 chairside test<br>Test group. The aMMP-8 chairside mouth rinse test is performed for the test group.It identifies adolescents with poor oral hygiene at risk for subclinical periodontitis without detectable and visible manifestations of the illness, such as periodontal deepened pockets. | Diagnostic Test: aMMP-8 chairside test<br>* No test<br>* Other names: No test;|
| No Intervention: No test<br>The other group is control group. No test administered. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| aMMP-8 test | Mouth rinse samples are analysed by method for chair-side diagnostic testing: the aMMP-8 specific lateral-ﬂow point-of-care (PoC)/chair-side test (PerioSafe®, Dentognostics GmbH, Jena, Germany). The result is provided in 5 minutes and is graded by eye as positive or negative. One line means that the test is negative but successfully done and two lines the test is positive. | 1 year |
Characteristics of Women With Reproductive Concerns

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect data that will be generated during an office visit. The data will be gathered and analyzed in research studies that will help with the investigators understanding of various medical conditions. About 200 subjects will be participating in this study. Participation in this study will not require a patient's time or presence. The medical information contained in a patient's chart from the office visit, including the results of any tests that were ordered at that time, will be transferred to an anonymous database and analyzed together with data from other patients who have similar condition/s. No follow-up information will be collected. The following information will be collected from a patient's medical record: the medical history and a list of the current medications.

Detailed Description
-----------------
Purpose: To collect the characteristics of patients presenting to the reproductive endocrinology clinic. Rationale: Patients' characteristics will be analyzed as part of clinical research studies and may help in understanding the causes of their condition.

Official Title
-----------------
Clinical Characteristics of Women Presenting to the Reproductive Endocrinology Clinic

Conditions
-----------------
Endocrine Disorders of Female Reproductive System

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: females of childbearing potential experiencing reproductive endocrinology related problems Exclusion Criteria: male or female not of childbearing potential

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Data collection from patients' charts. | Data collection from patients' charts. | up to 1 year from the time of signing the informed consent for data collection |
Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels. The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

Detailed Description
-----------------
Primary Outcome Measures: To correlate elevated serum NGAL with the diagnosis of intrinsic acute kidney injury in septic shock Secondary Outcome Measures : To compare serum NGAL with serum creatinine, serum urea and urine output in septic AKI Death within the intensive care unit Death from all causes at 28 days after inclusion

Official Title
-----------------
Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

Conditions
-----------------
Acute Kidney Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients showing signs of infection and hypotension requiring the use of epinephrine despite of an appropriate fluid challenge. 18 years of age or older Exclusion Criteria: Age under 18 years Prisoners or other institutionalized or vulnerable individuals Participation in an interventional clinical study within the previous 30 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Septic shock<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
septic shock, medical intensive care
Alternate-Day Buprenorphine Administration. Phase VII - 8

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.

Official Title
-----------------
Alternate-Day Buprenorphine Administration. Phase VII

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Opioid withdrawal |  |  | 
| Opioid agonist effects |  |  | 
| Pupil diameter |  |  |
Bioavailability and Effectiveness of Transdermally Administered Morphine

Study Overview
=================
Brief Summary
-----------------
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously.

Detailed Description
-----------------
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously. Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes.

Official Title
-----------------
Bioavailability and Effectiveness of Transdermally Administered Morphine

Conditions
-----------------
Cancer, Pain

Intervention / Treatment
-----------------
* Drug: morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic cancer pain Minimum baseline pain of 3/10 No change in medications over 3 days prior to study period Ability to give informed consent Willingness to undergo repeated blood sampling Exclusion Criteria: Use of morphine or codeine in 3 days prior to study Known sensitivity to morphine Prior anaphylactic reaction to any opioid Clinically significant anemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: morphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detectable morphine levels in serum |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, transdermal morphine, cancer, bioavailability, pharmacokinetics, cancer related pain, stable baseline pain, currently taking opioids
The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare fasting and postprandial PYY levels between overweight/obese and lean subjects during and after an infusion of saline, PYY1-36 or PYY3-36 and to evaluate the efects on appetite, energy intake and energy expenditure.

Detailed Description
-----------------
The study is a randomised dobbelblinded placebo controlled study with 24 male subjects ( 12 lean and 12 overweight/obese subjects). VAS scores are used to assess appetite and two ad libitum meals are served in the hours following the infusion. Energy expenditure is measured by ventilated hood system and blood is sampled during part of the study day.

Official Title
-----------------
Fasting and Postprandial Response After Infusion of Saline, PYY1-36 and PYY3-36 and Effects on Appetite, Energy Intake and Energy Expenditure in Overweight/Obese Compared to Normalweight Subjects

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Drug: Peptide YY infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2) Body weight fluctuations < 5 kg over the past 2 months. Blood pressure normal to mildly hypertensive (<159/99 mm Hg) Non-elite athletes and not planning to change physical activity during the study. Exclusion Criteria: Any physiological or psychological illnesses that could influence the study results Regular use of medicine Smoking defined as <1 cigarette per day. Substance abuse or dependence. Blood donation within the past 3 months before entering the study Drinking >21 alcoholic units/week. Food allergies. Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Peptide YY infusion|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appetite |  |  | 
| Energy intake |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy expenditure and substrate oxidation |  |  | 
| Blood parameters |  |  | 
| Blood pressure and heart rate |  |  |
Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

Study Overview
=================
Brief Summary
-----------------
The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy. A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.

Official Title
-----------------
P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.

Conditions
-----------------
Mycoses

Intervention / Treatment
-----------------
* Drug: Posaconazole or alternative fungal treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Immunocompromised patients with refractory IFI Patients eligible for prophylactic treatment due to anticipated neutropenia for more than 7 days. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections | Drug: Posaconazole or alternative fungal treatment<br>* Dosage of Posaconazole: Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: adverse events |  | Depending on treatment modality every 2 to 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baseline: Patient demographic data; Disease history; Underlying diseases; Diagnosis; Previous therapies; Environmental risk factors; Host factors Performance status |  | Depending on treatment modality every 2 to 4 weeks | 
| Treatment and follow up period: Performance status; Medication; Duration of treatment; Frequency of infectious episodes; Management of infections |  | Depending on treatment modality every 2 to 4 weeks | 
| Adverse events; Survival status |  | Depending on treatment modality every 2 to 4 weeks |
A Model for Risk Prediction of Fracture in Diabetic Patients With Osteoporosis

Study Overview
=================
Brief Summary
-----------------
The fracture risk of diabetic patients proves to be higher than those without diabetesdue to thehyperglycemia, usage of diabetes drugs, the changes in insulin levels and excretion, and this risk begins as early as adolescence.Many factors may be related to bone metabolism in patients with diabetes, including demographic data (e.g. age, height, weight, gender), medical history (e.g. smoking, drinking, menopause) and examination (e.g. bone mineral density, blood routine), urine routine).However, most of existing methods are qualitative assessments and do not take the interactions of the physiological factors of humans into consideration. In addition, the fracture risk of diabetic patients with osteoporosis has not been further studied before. In order to investigate the effect of patients' physiological factors on fracture risk, in the paper, we used a hybrid model combining XGBoost with deep neural network to predict the fracture risk of diabetic patients with osteoporosis.

Official Title
-----------------
A Model for Risk Prediction of Fracture in Diabetic Patients With Osteoporosis

Conditions
-----------------
Healthcare; Risk Prediction; Diabetic Patients With Osteoporosis

Intervention / Treatment
-----------------
* Other: Risk Prediction of Fracture in Diabetic Patients with Osteoporosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in Hospital's outpatient and inpatient His database between July 2012 and November 2022, diabetic patients were combined with osteoporosis. Exclusion Criteria: Patients with fractures before diagnosis of diabetes; patients with fractures before diagnosis of osteoporosis; patients with hyroid disease and other diseases that seriously affect bone metabolism.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fracture |  | 2-10 year |
Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation - a Randomised Study

Study Overview
=================
Brief Summary
-----------------
In this study we want to examine the effect of a small amount of local anesthetic or saline solution on nerve conduction using a peripheral nerve stimulator.

Detailed Description
-----------------
Using electrical nerve stimulation in performing peripheral nerve helps to control the needle position in relation to the nerve and therefore may increase the likelihood of a successful nerve block. Defining the minimal stimulating current accepted also may help to avoid direct contact between nerve and needle or accidental endoneural injection and subsequent nerve lesion. In recent years there have been many reports where several nerves, parts thereof or plexuses have been anesthetised using a multiple injection approach. That is, nerves in close proximity of each other have been subsequently blocked after using a nerve stimulator to locate them. It is not clear though, whether a nerve may already be partially anesthetised in this situation and whether that would impair the correct use of a peripheral nerve stimulator. The aim of this study is to examine the excitability of a peripheral nerve after injecting a small amount of local anesthetic agent or saline solution into the proximity of the nerve.

Official Title
-----------------
Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation - a Randomised, Double-Blind, Multicenter Study About the Stimulability of Anesthetized Nerves

Conditions
-----------------
Percutaneous Electric Nerve Stimulation

Intervention / Treatment
-----------------
* Procedure: peripheral nerve stimulation (procedure)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 1-2 Exclusion Criteria: peripheral neuropathy, ASA >2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: peripheral nerve stimulation (procedure)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peripheral nerve stimulation, saline, local anesthestics, regional anesthestia, nerve damage
Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma

Study Overview
=================
Brief Summary
-----------------
This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.

Official Title
-----------------
Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma

Conditions
-----------------
Nasopharyngeal Carcinoma

Intervention / Treatment
-----------------
* Drug: Cisplatin
* Drug: Nedaplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age≥18,T1-2aN1-3;T2-4NxNPC,VEGFR+,++,KPS>70,Life expectancy≥6 months, No uncontrolled hypertension,cardiac failure,diabetes,lunacy Exclusion Criteria: Distant metastasis, recurrent disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Cisplatin<br>cisplatin combine with IMRT | Drug: Cisplatin<br>* 40mg/m2/w<br>|
| Experimental: Nedaplatin<br>Nedaplatin combine with IMRT | Drug: Nedaplatin<br>* 40mg/m2/w<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| locoregionally control rate | 3 months after treatment | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | 1 year Progress Free Survival,Disease Free Survival,3 years and 5 years Over All Survival,Safety | 1,3,5 years |